$CV

Edwards Lifesciences (EW) received FDA approval for a pediatric heart valve. Ceribell (CBLL) and SI-BONE (SIBN) cleared new software and spinal fusion systems. Teva (TEVA) added a biosimilar to its portfolio. AbbVie (ABBV) and Mirum (MIRM) gained FDA approvals for Parkinson's and rare disease treatments. Merck (MRK) withdrew a lung cancer drug filing. Sanofi (SNY) and Regeneron (REGN) expanded their immunology alliance.

CapsoVision (CV) received FDA clearance for its AI Highlights tool, designed to assist physicians in reviewing small bowel capsule endoscopy studies. The tool reduces review time by marking suspected abnormal lesions. AI Highlights integrates with CapsoView and CapsoCloud platforms. CV's stock is currently trading at $6.63, down 0.38%.

CapsoVision, Inc (CV) filed an SEC Form 8-K — Other Events. Exhibit 99.1 CapsoVision Announces FDA Clearance of AI Highlights for CapsoCam Plus® AI-assisted reading tool designed to aid physician review of small bowel capsule endoscopy studies performed due to suspected bleeding using the CapsoCam Plus® system SARATOGA, Calif., September

CapsoVision (CV) director bought $9.9M shares at $5.69 each. Corebridge (CRBG) 10% owner Nippon Life bought $7.47M shares at $35.08. Inhibrx (INBX) director bought $500K shares at $100. Diamondback (FANG) director sold $15.32M shares at $204.31. Arista (ANET) CTO sold $8.82M shares near 52-week high. Duolingo (DUOL) CEO sold $6.17M shares at $150-$152. Asana (ASAN) CEO sold $4.2M shares. Robinhood (HOOD) CEO sold $32.55M shares.

HARARI ELIYAHOU ET AL purchased 1,757,469 indirectly-held shares of CapsoVision, Inc (CV) at $5.69 ($10.00M total) across 2 trades on 2026-09-18.

Shen Ching Hang purchased 878,734 indirectly-held shares of CapsoVision, Inc (CV) at $5.69 ($5.00M total) on 2026-09-15.

CapsoVision, Inc (CV) filed an SEC Form 8-K — Entry into a Material Definitive Agreement. Item 1.01. Entry into a Material Definitive Agreement. On September 17, 2026, CapsoVision, Inc. (the “Company”) entered into a securities purchase agreement (the “Purchase Agreement”) with certain investors (the “Purchasers”), which provides for the issuance and sale, in a regist

CapsoVision, Inc (CV) filed an SEC Form 8-K — Results of Operations and Financial Condition. Exhibit 99.1 CapsoVision Reports Second Quarter 2026 Financial Results SARATOGA, Calif., August 13, 2026 - CapsoVision, Inc. (NASDAQ: CV), a commercial-stage medical technology company developing advanced imaging and AI-enabled capsule endoscopy solutions, today reported financia

CapsoVision (NASDAQ: CV) said it launched its AI Highlights feature for the CapsoCam Plus capsule endoscopy system in international markets, including the EU. The AI flags suspected clinically relevant frames during standard processing and integrates with CapsoView and CapsoCloud workflows. The update is offered where authorized; it is not cleared by the FDA for US sale.

HARARI ELIYAHOU ET AL purchased 61,068 indirectly-held shares of CapsoVision, Inc (CV) at $6.73 ($0.41M total) on 2026-07-17.